Back to News
Market Impact: 0.55

Patient Square to Take Premier Private in $2.6 Billion Deal

KKRPINC
M&A & RestructuringPrivate Markets & VentureHealthcare & Biotech
Patient Square to Take Premier Private in $2.6 Billion Deal

Patient Square Capital has agreed to acquire health-services company Premier Inc. for $2.6 billion in an all-cash deal. The offer of $28.25 per share represents a 23.8% premium to Premier's 60-day average price, with the transaction expected to close by the first quarter of next year. This acquisition marks a significant private equity investment in the healthcare sector.

Analysis

Patient Square Capital has entered into a definitive agreement to acquire health-services company Premier Inc. (PINC) in a $2.6 billion all-cash transaction. The offer price of $28.25 per share represents a significant 23.8% premium to Premier's 60-day average price and is also above its last closing price of $25.75. This take-private deal, led by the investment firm of former KKR dealmaker Jim Momtazee, highlights strong private equity interest in the healthcare services sector. The transaction is slated for completion by the first quarter of the following year, at which point Premier will be delisted. The substantial premium and definitive nature of the agreement are the key drivers behind the strongly positive sentiment signal for Premier Inc.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

strongly positive

Sentiment Score

0.75

Ticker Sentiment

KKR0.00
PINC0.80

Key Decisions for Investors

  • Existing shareholders of Premier Inc. (PINC) should recognize this as a liquidity event offering a defined exit at a significant premium, with the deal's value locked in at $28.25 per share pending closure.
  • For merger arbitrage specialists, the primary play is the spread between Premier's current market price and the cash offer, balanced against the time value of money and the perceived risk of the deal not closing by the Q1 target.
  • Investors in the broader healthcare services industry should view this transaction as a positive valuation catalyst, potentially signaling further private equity-led consolidation and a re-rating of comparable peer companies.